WO2010026168A3 - Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b - Google Patents

Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b Download PDF

Info

Publication number
WO2010026168A3
WO2010026168A3 PCT/EP2009/061359 EP2009061359W WO2010026168A3 WO 2010026168 A3 WO2010026168 A3 WO 2010026168A3 EP 2009061359 W EP2009061359 W EP 2009061359W WO 2010026168 A3 WO2010026168 A3 WO 2010026168A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
cell mediated
gamma receptor
treatment
mediated multiple
Prior art date
Application number
PCT/EP2009/061359
Other languages
English (en)
Other versions
WO2010026168A2 (fr
Inventor
Peter Buckel
Uwe Jacob
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Priority to RU2011112857/15A priority Critical patent/RU2522251C2/ru
Priority to CA2735085A priority patent/CA2735085C/fr
Priority to AU2009289280A priority patent/AU2009289280C1/en
Priority to NZ591140A priority patent/NZ591140A/xx
Priority to JP2011525541A priority patent/JP5519674B2/ja
Priority to US13/062,115 priority patent/US20110230391A1/en
Priority to EP09782523A priority patent/EP2331114B1/fr
Priority to ES09782523T priority patent/ES2386335T3/es
Publication of WO2010026168A2 publication Critical patent/WO2010026168A2/fr
Publication of WO2010026168A3 publication Critical patent/WO2010026168A3/fr
Priority to US13/912,859 priority patent/US20130303458A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne le récepteur Fcγ (récepteur Fc-gamma) pour utilisation dans le traitement de la sclérose en plaques, où la sclérose en plaques est une forme véhiculée par les lymphocytes B de sclérose en plaques et/ou une forme véhiculée par auto-anticorps de sclérose en plaques. L’invention concerne des compositions pharmaceutiques contenant le récepteur Fcγ (récepteur Fc-gamma) pour utilisation dans le traitement de la sclérose en plaques, où la sclérose en plaques est une forme véhiculée par les lymphocytes B de sclérose en plaques et/ou une forme véhiculée par auto-anticorps de sclérose en plaques.
PCT/EP2009/061359 2008-09-05 2009-09-02 Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b WO2010026168A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
RU2011112857/15A RU2522251C2 (ru) 2008-09-05 2009-09-02 Вещества и способы лечения рассеянного склероза, опосредованного в клетками
CA2735085A CA2735085C (fr) 2008-09-05 2009-09-02 Recepteur fc gamma iib destine au traitement de sclerose en plaque mediee par cellule beta
AU2009289280A AU2009289280C1 (en) 2008-09-05 2009-09-02 FC gamma receptor for the treatment of B cell mediated multiple sclerosis
NZ591140A NZ591140A (en) 2008-09-05 2009-09-02 Fc gamma receptor for the treatment of b cell mediated multiple sclerosis
JP2011525541A JP5519674B2 (ja) 2008-09-05 2009-09-02 Ｂ細胞媒介性多発性硬化症の治療のための物質および方法
US13/062,115 US20110230391A1 (en) 2008-09-05 2009-09-02 Fc gamma receptor for the treatment of b cell mediated multiple sclerosis
EP09782523A EP2331114B1 (fr) 2008-09-05 2009-09-02 Recepteur fc-gamma pour le traitement de la sclérose en plaques médiée par les lymphocytes b
ES09782523T ES2386335T3 (es) 2008-09-05 2009-09-02 Receptor Fc-gamma para el tratamiento de la esclerosis múltiple mediada por los linfocitos B
US13/912,859 US20130303458A1 (en) 2008-09-05 2013-06-07 Substances and methods for the treatment of b cell mediated multiple sclerosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08163800A EP2161031A1 (fr) 2008-09-05 2008-09-05 Recepteur Fc-gamma pour le traitement de la sclérose en plaques médiée par les lymphocytes B
EP08163800.9 2008-09-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/062,115 A-371-Of-International US20110230391A1 (en) 2008-09-05 2009-09-02 Fc gamma receptor for the treatment of b cell mediated multiple sclerosis
US13/912,859 Division US20130303458A1 (en) 2008-09-05 2013-06-07 Substances and methods for the treatment of b cell mediated multiple sclerosis

Publications (2)

Publication Number Publication Date
WO2010026168A2 WO2010026168A2 (fr) 2010-03-11
WO2010026168A3 true WO2010026168A3 (fr) 2010-05-27

Family

ID=40227712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/061359 WO2010026168A2 (fr) 2008-09-05 2009-09-02 Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b

Country Status (9)

Country Link
US (2) US20110230391A1 (fr)
EP (2) EP2161031A1 (fr)
JP (1) JP5519674B2 (fr)
AU (1) AU2009289280C1 (fr)
CA (1) CA2735085C (fr)
ES (1) ES2386335T3 (fr)
NZ (1) NZ591140A (fr)
RU (1) RU2522251C2 (fr)
WO (1) WO2010026168A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130108619A1 (en) * 2011-11-02 2013-05-02 Isaac Melamed Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
EP2796144A1 (fr) * 2013-04-26 2014-10-29 SuppreMol GmbH Formulations hautement concentrées de récepteurs Fc solubles
EA034176B1 (ru) 2013-10-16 2020-01-14 Зуппремоль Гмбх РАСТВОРИМЫЙ Fc-ГАММА РЕЦЕПТОР ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ БУЛЛЕЗНЫХ ЗАБОЛЕВАНИЙ
RU2699717C2 (ru) 2014-04-18 2019-09-09 Дзе Ресёч Фаундэйшен Фор Дзе Штат Юниверсити Ов Нью-Йорк Гуманизированные антитела к антигену Томсена-Фриденрайха

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175998A1 (en) * 2001-07-30 2005-08-11 Jin Nakahara Medicinal compositions containing fc receptor gamma-chain activator
WO2008091682A2 (fr) * 2007-01-23 2008-07-31 Zymogenetics, Inc. FCγRIA SOLUBLE ET MÉTHODES ASSOCIÉES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005867A1 (fr) 1989-10-13 1991-05-02 Amgen Inc. Isoformes d'erythropoietine
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JPH06117187A (ja) 1992-10-08 1994-04-26 Iseki Tory Tech Inc シールド掘削機
AU2346900A (en) 1998-11-30 2000-06-19 Eli Lilly And Company Erythropoietic compounds
EP1006183A1 (fr) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
DE60134003D1 (de) 2000-04-21 2008-06-26 Amgen Inc Verfahren und zusammensetzungen zur vermeidung und behandlung von anämie
WO2001082774A2 (fr) * 2000-04-21 2001-11-08 Rutgers, The State University Of New Jersey Procedes et compositions destines au diagnostic de la schizophrenie
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
BRPI0409650A (pt) 2003-09-09 2006-04-25 Warren Pharmaceuticals Inc métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
WO2006028956A2 (fr) * 2004-09-02 2006-03-16 Genentech, Inc. Anticorps anti-recepteur fcgammariib et correspondantes
EP1870422A1 (fr) * 2006-06-20 2007-12-26 SuppreMol GmbH Moyens pour le traitement de maladies caractérisées par une réaction immunitaire excessive
EP2057465A4 (fr) * 2006-08-09 2010-04-21 Homestead Clinical Corp Protéines spécifiques d'organes et procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175998A1 (en) * 2001-07-30 2005-08-11 Jin Nakahara Medicinal compositions containing fc receptor gamma-chain activator
WO2008091682A2 (fr) * 2007-01-23 2008-07-31 Zymogenetics, Inc. FCγRIA SOLUBLE ET MÉTHODES ASSOCIÉES

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHAEFER B ET AL: "Sa.31. Targeting Fcgamma Receptors in the Treatment of Multiple Sclerosis", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 119, 1 January 2006 (2006-01-01), pages S115 - S116, XP024911490, ISSN: 1521-6616, [retrieved on 20060101] *
TORKILDSEN O; VEDELER C A; NYLAND H I; MYHR K -M: "Fc gamma R and multiple sclerosis: an overview", ACTA NEUROLOGICA SCANDINAVICA, vol. 113, no. Suppl. 183, 2006, pages 61 - 63, XP009110961, ISSN: 0001-6314 *

Also Published As

Publication number Publication date
CA2735085A1 (fr) 2010-03-11
AU2009289280B8 (en) 2014-06-12
EP2331114A2 (fr) 2011-06-15
RU2522251C2 (ru) 2014-07-10
CA2735085C (fr) 2018-10-16
WO2010026168A2 (fr) 2010-03-11
ES2386335T3 (es) 2012-08-17
AU2009289280A1 (en) 2010-03-11
AU2009289280A8 (en) 2014-06-12
AU2009289280B2 (en) 2014-05-29
AU2009289280C1 (en) 2014-10-02
US20110230391A1 (en) 2011-09-22
JP5519674B2 (ja) 2014-06-11
EP2161031A1 (fr) 2010-03-10
NZ591140A (en) 2012-10-26
EP2331114B1 (fr) 2012-05-16
US20130303458A1 (en) 2013-11-14
JP2012502000A (ja) 2012-01-26
RU2011112857A (ru) 2012-10-10

Similar Documents

Publication Publication Date Title
WO2011103202A3 (fr) Modulateurs du récepteur des androgènes et leurs utilisations
WO2010132882A3 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2012055567A3 (fr) Utilisation de malononitrilamides dans la douleur neuropathique
WO2012037410A3 (fr) Modulateurs des récepteurs des oestrogènes et leurs utilisations
WO2011156518A3 (fr) Modulateur du récepteur oestrogénique et utilisation de ces derniers
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
WO2007076070A3 (fr) Modulateurs de recepteurs muscariniques
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
IN2012DN00971A (fr)
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
WO2011150156A3 (fr) Composés hétéroarylés et leurs procédés d'utilisation
WO2009126688A8 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
EP2318033B8 (fr) Compositions destinées au traitement de la douleur et/ou de l'inflammation
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
EP3578568A3 (fr) Polypeptides se liant aux récepteurs de cxcr2
WO2006023852A3 (fr) Modulateurs des recepteurs muscariniques
WO2008021375A3 (fr) Modulateurs de récepteurs muscariniques
WO2006058294A3 (fr) Modulateurs des recepteurs muscariniques
WO2007100664A3 (fr) Modulateurs des récepteurs muscariniques
WO2010055082A3 (fr) Nouvelle forme cristalline de malate de sunitinib
IL193479A0 (en) Modulators of muscarinic receptors
WO2010116282A8 (fr) Composés 4,5-dihydro-lh-pyrazole et leurs utilisations pharmaceutiques
TW200800954A (en) Novel crystal modifications
WO2010026168A3 (fr) Substances et procédés pour le traitement de la sclérose en plaques véhiculée par les lymphocytes b

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09782523

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009782523

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009289280

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 591140

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2735085

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009289280

Country of ref document: AU

Date of ref document: 20090902

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011525541

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011112857

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13062115

Country of ref document: US